The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood purification equipment market size reached US$ 18.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 27.3 Billion by 2027, exhibiting a growth rate (CAGR) of 6.62% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Blood purification equipment refers to the medical devices used for extracting and purifying the patient’s blood. The equipment withdraws the blood to remove impurities and pumps the purified blood back into the body. Some of the commonly used equipment include hemodialysis, blood filtration, continuous renal replacement therapy (CRRT), hemoperfusion and plasma exchange devices. They are commonly utilized for the treatment of organ or renal failures and immune-metabolic disorders and for plasmapheresis procedures and are widely used across hospitals, clinics and ambulatory surgical centers.
The increasing prevalence of metabolic, immune and kidney-related disorders across the globe is one of the key factors driving the growth of the market. Furthermore, rising geriatric population, which is more susceptible to ailments, such as diabetes, hypertension and renal failure, is providing a thrust to the market growth. As the coronavirus disease (COVID-19) continues to spread, there is a significant increase in the requirement for blood purification devices across healthcare centers. These devices filter the pathogens, cytokines and other inflammatory mediators from the blood to improve the cell's immune response. Additionally, various product innovations, such as the development of equipment with biofeedback loops and personalized dialysis prescription capabilities, are acting as other growth-inducing factors. These novel variants aid in preventing intradialytic hypotension, improving monitoring during dialysis and maintaining electronic medical records (EMRs). In line with this, product manufacturers are also developing portable and economical blood purification equipment, which can be used for at-home care settings. Other factors, including rising health consciousness among the masses, along with improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood purification equipment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, indication and end user.
Breakup by Product Type:
Breakup by Indication:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aethlon Medical Inc., Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, CytoSorbents Corporation, Fresenius SE & Co. KGaA, Healthwell Medical Tech. Co. Ltd., Jafron Biomedical Co. Ltd., Kaneka Corporation, Medtronic plc, Nikkiso Co ltd., and Spectral Medical Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Indication, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Aethlon Medical Inc., Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, CytoSorbents Corporation, Fresenius SE & Co. KGaA, Healthwell Medical Tech. Co. Ltd., Jafron Biomedical Co. Ltd., Kaneka Corporation, Medtronic plc, Nikkiso Co ltd., and Spectral Medical Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global blood purification equipment market was valued at US$ 18.1 Billion in 2021.
We expect the global blood purification equipment market to exhibit a CAGR of 6.62% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for blood purification equipment to filter the pathogens, cytokines, and other inflammatory mediators from the blood to improve the immunity against the coronavirus infection.
The rising prevalence of metabolic, immune, and kidney-related disorders, along with the growing adoption of blood purification equipment for treating organ or renal failures and plasmapheresis procedures, is primarily driving the global blood purification equipment market.
Based on the product type, the global blood purification equipment market can be categorized into portable and stationary. Currently, portable accounts for the majority of the global market share.
Based on the indication, the global blood purification equipment market has been segregated into sepsis, renal diseases, and others. Among these, renal diseases currently hold the largest market share.
Based on the end user, the global blood purification equipment market can be bifurcated into hospitals and clinics, dialysis centers, and others. Currently, dialysis centers exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.
Some of the major players in the global blood purification equipment market include Aethlon Medical Inc., Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, CytoSorbents Corporation, Fresenius SE & Co. KGaA, Healthwell Medical Tech. Co. Ltd., Jafron Biomedical Co. Ltd., Kaneka Corporation, Medtronic plc, Nikkiso Co ltd., and Spectral Medical Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at